WO2005007081A3 - Compounds and methods for delivery of prostacyclin analogs - Google Patents

Compounds and methods for delivery of prostacyclin analogs Download PDF

Info

Publication number
WO2005007081A3
WO2005007081A3 PCT/US2004/016401 US2004016401W WO2005007081A3 WO 2005007081 A3 WO2005007081 A3 WO 2005007081A3 US 2004016401 W US2004016401 W US 2004016401W WO 2005007081 A3 WO2005007081 A3 WO 2005007081A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
methods
prostacyclin analogs
delivery
present
Prior art date
Application number
PCT/US2004/016401
Other languages
French (fr)
Other versions
WO2005007081A9 (en
WO2005007081A2 (en
Inventor
Ken Phares
David Mottola
Original Assignee
United Therapeutics Corp
Ken Phares
David Mottola
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34079029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005007081(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by United Therapeutics Corp, Ken Phares, David Mottola filed Critical United Therapeutics Corp
Priority to ES04776104T priority Critical patent/ES2622471T5/en
Priority to CA2526534A priority patent/CA2526534C/en
Priority to JP2006533395A priority patent/JP5043433B2/en
Priority to EP04776104.4A priority patent/EP1628654B2/en
Publication of WO2005007081A2 publication Critical patent/WO2005007081A2/en
Publication of WO2005007081A3 publication Critical patent/WO2005007081A3/en
Priority to KR1020057022319A priority patent/KR101072339B1/en
Publication of WO2005007081A9 publication Critical patent/WO2005007081A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
    • C07C59/13—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C07C69/712—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings

Abstract

This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally. Compounds of the present invention have formula (I).
PCT/US2004/016401 2003-05-22 2004-05-24 Compounds and methods for delivery of prostacyclin analogs WO2005007081A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES04776104T ES2622471T5 (en) 2003-05-22 2004-05-24 Compounds and procedures for the administration of prostacyclin analogs
CA2526534A CA2526534C (en) 2003-05-22 2004-05-24 Compounds and methods for delivery of prostacyclin analogs
JP2006533395A JP5043433B2 (en) 2003-05-22 2004-05-24 Compounds and methods for delivery of prostacyclin analogs
EP04776104.4A EP1628654B2 (en) 2003-05-22 2004-05-24 Compounds and methods for delivery of prostacyclin analogs
KR1020057022319A KR101072339B1 (en) 2003-05-22 2005-11-22 Compounds and methods for delivery of prostacyclin analogs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47240703P 2003-05-22 2003-05-22
US60/472,407 2003-05-22

Publications (3)

Publication Number Publication Date
WO2005007081A2 WO2005007081A2 (en) 2005-01-27
WO2005007081A3 true WO2005007081A3 (en) 2005-04-14
WO2005007081A9 WO2005007081A9 (en) 2017-01-26

Family

ID=34079029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/016401 WO2005007081A2 (en) 2003-05-22 2004-05-24 Compounds and methods for delivery of prostacyclin analogs

Country Status (8)

Country Link
US (19) US7417070B2 (en)
EP (2) EP2792353B1 (en)
JP (2) JP5043433B2 (en)
KR (1) KR101072339B1 (en)
CN (4) CN102697790A (en)
CA (4) CA2851309C (en)
ES (2) ES2622471T5 (en)
WO (1) WO2005007081A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371264B2 (en) 2013-01-11 2016-06-21 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
KR102541885B1 (en) 2016-09-26 2023-06-12 유나이티드 쎄러퓨틱스 코포레이션 treprostinil prodrug
US11958822B2 (en) 2022-10-14 2024-04-16 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10214983A1 (en) * 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Nebulisable liposomes and their use for pulmonary application of active substances
CN102697790A (en) * 2003-05-22 2012-10-03 联合治疗公司 Compounds and methods for delivery of prostacyclin analogs
US20090124697A1 (en) 2003-12-16 2009-05-14 United Therapeutics Corporation Inhalation formulations of treprostinil
CA2549724C (en) * 2003-12-16 2014-02-11 United Therapeutics Corporation Use of treprostinil to treat and prevent ischemic lesions
DE602004022982D1 (en) * 2003-12-16 2009-10-15 United Therapeutics Corp USE OF TREPROSTINIL TO IMPROVE THE KIDNEY FUNCTION
KR101186029B1 (en) 2004-04-12 2012-09-27 유나이티드 쎄러퓨틱스 코포레이션 Use of treprostinil to treat neuropathic diabetic foot ulcers
KR20080029962A (en) * 2005-06-02 2008-04-03 더 리젠츠 오브 더 유니버시티 오브 콜로라도 Uses of prostacyclin analogs
US8747897B2 (en) * 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
US20080200449A1 (en) * 2006-05-15 2008-08-21 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
DE102006026786A1 (en) 2006-06-07 2007-12-13 Joachim Kern metered dose inhaler
US20090036465A1 (en) * 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
US20100048693A1 (en) * 2006-12-04 2010-02-25 The Regents Of The University Of Colorado, A Body Corporate Treatment of COPD
CN102648916A (en) 2007-02-09 2012-08-29 联合治疗公司 Treprostinil treatment for interstitial lung disease and asthma
CA2710205C (en) 2007-12-17 2016-04-26 United Therapeutics Corporation An improved process to prepare treprostinil, the active ingredient in remodulin
CN102015613B (en) * 2008-05-08 2013-07-31 联合治疗公司 Treprostinil monohydrate
WO2009158010A1 (en) * 2008-06-27 2009-12-30 Concert Pharmaceuticals, Inc. Prostacyclin analogs
WO2010129757A1 (en) * 2009-05-07 2010-11-11 United Therapeutics Corporation Solid formulations of prostacyclin analogs
CN101891596B (en) * 2009-05-22 2013-12-11 上海天伟生物制药有限公司 New compound and preparation method and application thereof
DE102009031274A1 (en) 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomes for pulmonary application
US20120184622A1 (en) 2009-08-07 2012-07-19 Scipharm Sarl Composition for the treatment of cystic fibrosis
EP3108888B1 (en) 2010-03-15 2020-02-12 United Therapeutics Corporation Treatment for pulmonary hypertension
EP2576492B1 (en) 2010-06-03 2017-09-20 United Therapeutics Corporation Treprostinil production
US20120004307A1 (en) * 2010-06-15 2012-01-05 United Therapeutics Corporation Oral treatment of digital ischemic lesions
CA2710725C (en) 2010-07-22 2017-08-01 Alphora Research Inc. Protected aldehydes for use as intermediates in chemical syntheses, and processes for their preparation
CA2726599C (en) 2010-12-30 2017-07-25 Alphora Research Inc. Process for treprostinil salt preparation
US10920242B2 (en) 2011-02-25 2021-02-16 Recombinetics, Inc. Non-meiotic allele introgression
JP5580491B2 (en) 2011-03-02 2014-08-27 ユナイテッド セラピューティクス コーポレイション Synthesis of intermediates for the production of treprostinil.
CN103193627B (en) 2012-01-10 2016-04-20 上海天伟生物制药有限公司 Crystal formation of a kind of prostaglandin analogue and its production and use
CN103193626B (en) 2012-01-10 2016-05-11 上海天伟生物制药有限公司 Crystal formation of a kind of prostaglandin analogue and its production and use
US9387214B2 (en) 2012-01-13 2016-07-12 United Therapeutics Corporation Method of identifying therapies for pulmonary hypertension
EP2674413B1 (en) * 2012-06-15 2017-06-07 SciPharm SàRL Process for the preparation of treprostinil and derivatives thereof
KR20150089087A (en) * 2012-11-30 2015-08-04 인스메드 인코포레이티드 Prostacylin compositions and methods for using the same
JP6342414B2 (en) * 2012-12-07 2018-06-13 ケイマン ケミカル カンパニー， インコーポレーテッド Method for synthesizing prostacyclin analogs
CN103880801B (en) * 2012-12-20 2017-11-03 江苏盛迪医药有限公司 A kind of intermediate for preparing treprostinil that, its preparation method and the method that treprostinil that is prepared by it
CA3212313A1 (en) * 2013-03-14 2014-10-02 United Therapeutics Corporation Solid forms of treprostinil
KR20150128903A (en) 2013-03-15 2015-11-18 유나이티드 세러퓨틱스 코오포레이션 Salts of treprostinil
US9102660B2 (en) 2013-03-25 2015-08-11 United Therapeutics Corporaiton Process of making prostacyclin compounds with linker thiol and pegylated forms
US9758465B2 (en) 2013-04-30 2017-09-12 United Therapeutics Corporation Controlled release pharmaceutical formulations
AU2014339866C1 (en) * 2013-10-25 2018-09-20 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
US9895465B2 (en) * 2014-03-12 2018-02-20 Pioneer Surgical Technology, Inc. Absorbable compositions and methods for their use in hemostasis
ES2908142T3 (en) 2014-06-13 2022-04-27 United Therapeutics Corp Treprostinil formulations
EP3828160A1 (en) 2014-07-16 2021-06-02 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
WO2016038532A1 (en) 2014-09-09 2016-03-17 Mylan Laboratories Limited Amorphous treprostinil diethanolamine
HU231184B1 (en) 2014-10-08 2021-07-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Treprostinyl-sodium-monohydrate and process for its preparation
JP6224872B1 (en) 2014-10-20 2017-11-01 ユナイテッド セラピューティクス コーポレイション Synthesis of intermediates to produce prostacyclin derivatives.
EP3221291B1 (en) * 2014-11-18 2021-03-31 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
TWI540121B (en) * 2014-12-01 2016-07-01 臺灣永光化學工業股份有限公司 Method and novel intermediate for preparing treprostinil diethanolamine
EP3226838A1 (en) 2014-12-03 2017-10-11 Steadymed Ltd. Preservative-free treprostinil formulations and methods and devices for use with same
CN104783298A (en) * 2015-03-24 2015-07-22 湖州珍贝羊绒制品有限公司 Preparation and application of biological sterilizing composition and nanoemulsion thereof
WO2016176555A1 (en) * 2015-04-29 2016-11-03 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
US9643911B2 (en) * 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US11069054B2 (en) 2015-12-30 2021-07-20 Visiongate, Inc. System and method for automated detection and monitoring of dysplasia and administration of immunotherapy and chemotherapy
MX2019002999A (en) * 2016-09-15 2019-07-18 Camurus Ab Prostacyclin analogue formulations.
JP2020500882A (en) 2016-12-05 2020-01-16 コルセア ファーマ インコーポレイテッド Dermal and transdermal administration methods of treprostinil and its salts
US10799653B2 (en) 2017-01-09 2020-10-13 United Therapeutics Corporation Aerosol delivery device and method for manufacturing and operating the same
EP3498283A1 (en) * 2017-12-14 2019-06-19 Ipsol AG Glycosidic derivatives of treprostinil
HU231296B1 (en) 2018-03-09 2022-09-28 Chinoin Zrt Process for the preparation of the b polymorph form of treprostinil-diethanol-amine salt
CN112384224A (en) * 2018-05-07 2021-02-19 国邑药品科技股份有限公司 Pharmaceutical compositions for controlling the release of treprostinil
EP3853200B1 (en) * 2018-09-18 2024-01-24 Eli Lilly and Company Erbumine salt of treprostinil
WO2020223237A1 (en) * 2019-04-29 2020-11-05 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
JP2020011957A (en) * 2019-07-22 2020-01-23 コルセア ファーマ インコーポレイテッド Treprostinil derivative compound and method of using the same
EP4017588A1 (en) * 2019-08-23 2022-06-29 United Therapeutics Corporation Treprostinil prodrugs
US10781160B1 (en) * 2019-10-04 2020-09-22 Chirogate International Inc. Hexadecyl Treprostinil crystals and methods for preparation thereof
EP4076398A4 (en) 2019-12-16 2024-01-03 Tenax Therapeutics Inc Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hf-pef)
IL296567A (en) 2020-04-17 2022-11-01 United Therapeutics Corp Treprostinil for use in the treatment of interstitial lung disease
CA3180230A1 (en) 2020-06-09 2021-12-16 Hitesh Batra Fumaryl diketopiperidine prodrugs of treprostinil
JP7138685B2 (en) * 2020-10-26 2022-09-16 コルセア ファーマ インコーポレイテッド Treprostinil derivative compounds and methods of use thereof
US11447440B2 (en) 2020-10-29 2022-09-20 Chirogate International Inc. Treprostinil monohydrate crystals and methods for preparation thereof
JP2023553989A (en) 2020-12-14 2023-12-26 ユナイテッド セラピューティクス コーポレイション How to treat diseases with treprostinil prodrugs
KR20240012354A (en) 2021-03-03 2024-01-29 유나이티드 쎄러퓨틱스 코포레이션 Treprostinil, further comprising (E)-3,6-bis[4-(N-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (FDKP), and Dry powder composition of its prodrug
CN113552265B (en) * 2021-09-17 2022-01-04 天地恒一制药股份有限公司 Method for detecting impurities in raw materials for synthesizing propane fumarate tenofovir and application
WO2023154705A1 (en) 2022-02-08 2023-08-17 United Therapeutics Corporation Treprostinil iloprost combination therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234953A (en) * 1990-05-24 1993-08-10 Burroughs Wellcome Co. Treatment of congestive heart failure

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US515322A (en) * 1894-02-27 Railroad-car
US3515222A (en) * 1968-06-19 1970-06-02 American Tractor Equip Corp Cable plow mounting
US4490537A (en) * 1977-04-19 1984-12-25 The Upjohn Company Enlarged-hetero-ring prostacyclin analogs
CA1201712A (en) * 1980-02-28 1986-03-11 Paul A. Aristoff Carbacyclin analogs
US4338457A (en) 1980-02-28 1982-07-06 The Upjohn Company Composition and process
US4525586A (en) 1980-02-28 1985-06-25 The Upjohn Company Composition and process
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
US4420632A (en) 1980-04-15 1983-12-13 The Upjohn Company Composition and process
US4306076A (en) 1980-04-23 1981-12-15 The Upjohn Company Inter-phenylene CBA compounds
US4349689A (en) * 1980-12-22 1982-09-14 The Upjohn Company Methano carbacyclin analogs
US4434164A (en) 1981-06-01 1984-02-28 Pfizer Inc. Crystalline benzothiazine dioxide salts
US4486598A (en) 1982-02-22 1984-12-04 The Upjohn Company Carbacyclin analogs
DE3315356A1 (en) * 1982-04-30 1983-11-17 Ono Pharmaceutical Co. Ltd., Osaka USE OF PROSTAGLANDINE ANALOGS
US4561604A (en) 1983-07-18 1985-12-31 Shimano Industrial Company Limited Spinning reel
FI67490C (en) 1983-11-02 1985-04-10 Fluilogic Systems Oy FILTRERINGSENHET
US4744989A (en) 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
US4683330A (en) 1984-03-08 1987-07-28 The Upjohn Company Interphenylene carbacyclin derivatives
CA1241324A (en) 1984-03-08 1988-08-30 Paul A. Aristoff Interphenylene carbacyclin derivatives
US4668814A (en) * 1984-03-08 1987-05-26 The Upjohn Company Interphenylene carbacyclin derivatives
DE3427797A1 (en) 1984-07-25 1986-02-06 Schering AG, 1000 Berlin und 4709 Bergkamen Cytoprotective effect of prostacyclin derivatives on liver, pancreas gland and kidney
US5663203A (en) 1986-09-11 1997-09-02 Schering Aktiengesellschaft Agents containing prostacyclin derivatives for topical application
GB8824187D0 (en) 1988-10-14 1988-11-23 Wellcome Found Compounds for use in medicine
GB8814438D0 (en) * 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
US5545671A (en) * 1989-10-05 1996-08-13 Schering Aktiengesellschaft Antimetastically acting agents
DE4104606C1 (en) 1991-02-12 1992-10-15 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
US5496850A (en) * 1991-04-11 1996-03-05 Toray Industries, Inc. Antimetastasis agent of malignant tumors
DE4135193C1 (en) * 1991-10-22 1993-03-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
US5190972A (en) 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
DE4202665A1 (en) 1992-01-28 1993-07-29 Schering Ag PROSTACYCLIN AND CARBACYCLINE DERIVATIVES AS A MEDIUM FOR TREATING MULTIPLE Sclerosis
US6171786B1 (en) 1992-09-17 2001-01-09 Board Of Trustees Of University Of Illinois Methods for preventing multidrug resistance in cancer cells
US5466203A (en) * 1994-03-30 1995-11-14 Chen; George Magnetically controlled load adjusting structure of gymnastic apparatus
CA2269707C (en) 1996-10-25 2005-08-16 Edward M. Rudnic Soluble form osmotic dose delivery system
JP3744941B2 (en) 1997-03-14 2006-02-15 東レ株式会社 Prostaglandin I derivative sustained-release preparation
US6451815B1 (en) * 1997-08-14 2002-09-17 Aventis Pharmaceuticals Inc. Method of enhancing bioavailability of fexofenadine and its derivatives
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2307163C (en) 1997-10-24 2014-05-06 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
WO1999025357A1 (en) * 1997-11-14 1999-05-27 United Therapeutics Corporation USE OF 9-DEOXY-2', 9-α-METHANO-3- OXA-4,5,6- TRINOR-3, 7-(1',3'-INTERPHENYLENE) -13,14-DIHYDRO- PROSTAGLANDIN F1 TO TREAT PERIPHERAL VASCULAR DISEASE
US20010038855A1 (en) 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
ES2296613T3 (en) * 1999-03-18 2008-05-01 Queen Mary And Westfield College INHIBITORS OF ENDOTHELINE SYNTHESIS-1.
CN1354622A (en) * 1999-03-31 2002-06-19 联合治疗公司 Prostaglandin compound, compositions and methods of treating peripheral vascular disease and pulmonary hypertension
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
US6242482B1 (en) * 2000-06-05 2001-06-05 United Therapeutics Corporation Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure
US20020076382A1 (en) * 2000-08-04 2002-06-20 Kaplan Leonard W. Formulations of mometasone and a bronchodilator for pulmonary administration
EP1341476A2 (en) 2000-12-01 2003-09-10 Nephros Therapeutics, Inc. Intrasvascular drug delivery device and use therefor
US6700025B2 (en) 2001-01-05 2004-03-02 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
US20030108512A1 (en) * 2001-12-10 2003-06-12 Robert Shorr Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the treatment of cancer
US6803386B2 (en) * 2002-01-16 2004-10-12 United Therapeutics Corporation Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
US7132453B2 (en) 2002-03-15 2006-11-07 Vanderbilt University Method of using prostacyclin to treat respiratory syncytial virus infections
DE10214983A1 (en) 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Nebulisable liposomes and their use for pulmonary application of active substances
CN102697790A (en) 2003-05-22 2012-10-03 联合治疗公司 Compounds and methods for delivery of prostacyclin analogs
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
US20050254032A1 (en) 2003-11-13 2005-11-17 Fuji Photo Film Co., Ltd. Exposure device
CA2549724C (en) 2003-12-16 2014-02-11 United Therapeutics Corporation Use of treprostinil to treat and prevent ischemic lesions
CN102648916A (en) 2007-02-09 2012-08-29 联合治疗公司 Treprostinil treatment for interstitial lung disease and asthma
CA2710205C (en) * 2007-12-17 2016-04-26 United Therapeutics Corporation An improved process to prepare treprostinil, the active ingredient in remodulin
CN102015613B (en) * 2008-05-08 2013-07-31 联合治疗公司 Treprostinil monohydrate
JP2010244388A (en) * 2009-04-08 2010-10-28 Pioneer Electronic Corp Information providing apparatus, information providing method, and program for information provision
WO2010129757A1 (en) 2009-05-07 2010-11-11 United Therapeutics Corporation Solid formulations of prostacyclin analogs
EP2576492B1 (en) * 2010-06-03 2017-09-20 United Therapeutics Corporation Treprostinil production

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234953A (en) * 1990-05-24 1993-08-10 Burroughs Wellcome Co. Treatment of congestive heart failure

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371264B2 (en) 2013-01-11 2016-06-21 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
KR102541885B1 (en) 2016-09-26 2023-06-12 유나이티드 쎄러퓨틱스 코포레이션 treprostinil prodrug
US11958822B2 (en) 2022-10-14 2024-04-16 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same

Also Published As

Publication number Publication date
US8252839B2 (en) 2012-08-28
US8410169B2 (en) 2013-04-02
US20190345091A1 (en) 2019-11-14
ES2622471T3 (en) 2017-07-06
US20160051505A1 (en) 2016-02-25
US9624156B2 (en) 2017-04-18
US20070082948A1 (en) 2007-04-12
US20150259274A1 (en) 2015-09-17
ES2622471T5 (en) 2020-07-23
CA2526534A1 (en) 2005-01-27
US8232316B2 (en) 2012-07-31
EP2792353A3 (en) 2015-03-25
ES2670872T3 (en) 2018-06-01
JP5043433B2 (en) 2012-10-10
CA2526534C (en) 2011-07-12
US20130261187A1 (en) 2013-10-03
JP2007501281A (en) 2007-01-25
CN101780092A (en) 2010-07-21
US20180141891A1 (en) 2018-05-24
US20110118213A1 (en) 2011-05-19
US20080249167A1 (en) 2008-10-09
EP1628654B2 (en) 2019-12-04
US11292758B2 (en) 2022-04-05
EP1628654A2 (en) 2006-03-01
US10947177B2 (en) 2021-03-16
CA2851309C (en) 2017-04-18
EP1628654B1 (en) 2017-01-25
CN101265226A (en) 2008-09-17
US20050085540A1 (en) 2005-04-21
US20220289660A1 (en) 2022-09-15
WO2005007081A9 (en) 2017-01-26
US7384978B2 (en) 2008-06-10
CA2851309A1 (en) 2005-01-27
CN100558351C (en) 2009-11-11
US8536363B2 (en) 2013-09-17
US20220024845A1 (en) 2022-01-27
US9878972B2 (en) 2018-01-30
US20050282901A1 (en) 2005-12-22
US7544713B2 (en) 2009-06-09
US20070078095A1 (en) 2007-04-05
CN101265226B (en) 2013-04-24
US20160355455A1 (en) 2016-12-08
WO2005007081A2 (en) 2005-01-27
US20070078182A1 (en) 2007-04-05
CA2736406C (en) 2014-11-18
US20200181057A1 (en) 2020-06-11
US20120295980A1 (en) 2012-11-22
CN1822826A (en) 2006-08-23
US9278901B2 (en) 2016-03-08
JP2012162539A (en) 2012-08-30
US20150005374A1 (en) 2015-01-01
US9199908B2 (en) 2015-12-01
KR20060021862A (en) 2006-03-08
KR101072339B1 (en) 2011-10-11
EP1628654A4 (en) 2008-10-15
CN102697790A (en) 2012-10-03
US9050311B2 (en) 2015-06-09
CA2959852A1 (en) 2005-01-27
EP2792353A2 (en) 2014-10-22
CA2736406A1 (en) 2005-01-27
US9422223B2 (en) 2016-08-23
EP2792353B1 (en) 2018-02-28
US7417070B2 (en) 2008-08-26
US20160030371A1 (en) 2016-02-04
CN101780092B (en) 2012-07-04

Similar Documents

Publication Publication Date Title
WO2005007081A3 (en) Compounds and methods for delivery of prostacyclin analogs
RU2395500C2 (en) 2,4-pyrimidine diamines used in treating neoplastic diseases, inflammatory and immune disorders
JP6021805B2 (en) Tumor treatment
CA2534571A1 (en) Substituted isoquinoline derivatives and methods of use
JP2005507947A5 (en)
IL166298A0 (en) 8-hydroxy quinoline derivatives
CA2534570A1 (en) Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
AR067965A2 (en) COMPOUNDS CONTAINING LACTAMA INHIBITORS OF THE X COAGULATION FACTOR, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USES OF THEM IN THE TREATMENT OF THROMBOENMBOLIC DISORDERS.
HK1069339A1 (en) Substituted diketopiperazines as oxytocin antagonists
WO2002066480A3 (en) 2-arylamino-pyrimidines for the treatment of gsk3-related disorders
CN1284078A (en) Heterocycilc compounds for inhibition of gastric acid secretion, processes for their prepn. and pharmaceutical compsns thereof
ATE370138T1 (en) NEW IMIDAZOPYRIDINES AND THEIR USE
KR940005566A (en) Quinoline compounds
FI103409B1 (en) Process for the preparation of pharmaceutically useful benzimidazole derivatives
MA46608B1 (en) Liposomal formulation useful for the treatment of cancer
JP2020007357A (en) Organic compounds
JP2004502732A5 (en)
WO2001064645A3 (en) Derivatives of quinoline as alpha-2 antagonists
JP2012510957A5 (en)
MX2021011224A (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing.
ES2606925T3 (en) Deuterated benzopyran compound and application thereof
TW200509992A (en) Dosage form containing pantoprazole as active ingredient
TW200420554A (en) A intra-airway administrating preparation
JP2002529497A5 (en)
JP2003522768A5 (en)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480020569.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2526534

Country of ref document: CA

Ref document number: 2006533395

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020057022319

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2621/KOLNP/2005

Country of ref document: IN

REEP Request for entry into the european phase

Ref document number: 2004776104

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004776104

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004776104

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057022319

Country of ref document: KR